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involvement are as follows median age 45 (17-68) vs. 50
(16-82) (p¼0.0004), Disease status(standard/high
risk):63(40%)/94(60%) vs. 2361(48%)/2549(52%) (p¼0.0044).
The estimated OS, cumulative incidence (CI) of relapse and
non-relapse mortality in AML with CNS involvement were
comparable to those for AML without CNS involvement
(5-year OS, CI of relapse and NRM of AML with and without
CNS involvement was 38.5% vs. 39.9% (p¼0.847), 31.8% vs.
29.8% (p¼0.418) and 26.7% vs. 29.0%(p¼0.278) respectively).
Univariate analysis showed that age at allo-HSCT (older than
50 years), the absence of chronic graft versus host disease
(cGVHD), high risk of disease status (>¼3rdcomplete
response (CR3)/non-CR), worse ECOG performance status
(>¼2) and poor cytogenetic risk category according to
SWOG deﬁnition predicted worse OS in AML with CNS
involvement. Multivariate analysis showed that the devel-
opment of cGVHD, disease status and cytogenetic risk
category are independent prognostic factors for OS.
Conclusion: The current study showed that the outcomes of
allo-HSCT for AML with CNS involvement were comparable
to those of AML without CNS involvement. These results
suggest that allo-HSCT may overcome the poor prognosis of
AML with CNS involvement and should be an effective
therapeutic option for these patients.69
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Survivin is broadly expressed by hematological malig-
nancies and may be a suitable target for T-cell immuno-
therapy. Previously, the utility of this approach has been
challenged by the occurrence of “fratricide” when T cells
expressing a high avidity survivin-speciﬁc T cell receptor
(TCR) isolated from allogeneic cultures killed each other
because survivin epitopes can be presented by T cells
themselves (Leisegang M et al, J Clin Invest. 2010;120:3869).
To overcome this obstacle, we used autologous cultures to
isolate a new T-cell clone targeting the HLA-A*02-restricted
survivin95-104 epitope. This clone displayed nanomolar
avidity and speciﬁc killing against survivin+HLA-A*02+ leu-
kemia cells (BV173, 3916% speciﬁc lysis, E:T 40:1) and
multiple myeloma cells (U266, 207%) but not against HLA-
A*02e HL-60 cells (22%). Colony formation of primary
myeloid leukemias was inhibited (>50% reduction) while
that of healthy bone marrow (BM) was not. The TCR a- and
b-chains were cloned in a retroviral vector and used to
efﬁciently transduce CD8+ T cells (894%, n¼6). As
compared to non-transduced (NT) T cells, TCR+ T cells pro-
duced signiﬁcant lysis of BV173 (4614% vs 86%, E:T 20:1,
n¼12, p<0.001) and U266 (2712% vs 146%, p¼0.003) but
not of HL-60 (147 vs 146 %, p¼NS). TCR+ cells also
inhibited colony formation (32-78% reduction, n¼5) of pri-
mary myeloid leukemias while preserving normal clono-
genic capacity of BM or CB (n¼5). When tested in vivo in a
xenograft mouse model of leukemia (FFLuc+BV173) with
bioluminescent imaging, progression was signiﬁcantly
slower in mice treated with TCR+ versus NT T cells (8.1x106
 9x106 vs 195x106  85x106 photons/sec) (day 40,
p¼0.003, n¼10/group). Overall survival was improved (day80, p<0.001) and 3/10 mice treated with TCR+ T cells
completely cleared the leukemia. Crucially, the TCR cloned
from our autologous culture system produced no fratricidal
activity against HLA-A*02+ activated T cells (12%, E:T 20:1,
n¼7). To elucidate at the molecular level the selective
antitumor activity of our “autologous” TCR as opposed to
the fratricidal “allogeneic” TCRs, we modeled the structure
of each TCR-peptide-HLA ternary complex. While the overall
binding energies of TCR-peptide-HLA interfaces for both
TCRs were similar, the “autologous” TCR showed a 48%
higher binding energy contribution for the peptide as
compared to the fratricidal TCR, whose interaction was
primarily with the HLA molecule rather than with the sur-
vivin peptide in the HLA-binding groove. In conclusion, we
have cloned a novel survivin-TCR with a highly epitope-
speciﬁc binding mode that can be efﬁciently expressed in
polyclonal T cells and provides antitumor activity in vitro
and in vivowithout affecting the survival of T cells or normal
hematopoiesis. Our results indicate that maximal recogni-
tion of the peptide presented in the HLA groove is critical
for TCR selectivity.70
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Introduction: Extra-medullary (EM) leukemia is present in 3
e 8% of persons with AML. Although controversial, retro-
spective analyses have suggested an adverse impact on
outcomes of conventional therapy. Although use of allo-
transplants might overcome this adverse prognostic impact,
data supporting this approach are limited. Isolated EM
relapses occur after allotransplants and may reﬂect lack of
graft vs leukemia effect in EM sites. Also, the use of reduced-
intensity conditioning (RIC) regimens, T-cell-depleted grafts
and non-radiation-based conditioning regimens may be
associated with higher rates of EM relapse and similarly may
reduce the effectiveness of allotransplants in persons with
AML and EM leukemia.
Methods: Retrospective analysis of variables associated with
outcome of allotransplants for persons with AML with or
without EM leukemia pretransplant was performed. The
study population included subjects age 18-70 receiving
HLA-identical sibling or HLA-matched unrelated donor
transplants of bonemarrowor cells from1995-2010 reported
to the CIBMTR.
Results: 9797 subjects met the selection criteria, 814 (8%) of
whom had extra-medullary leukemia at different times
pretransplant. Median follow-up of survivors was 58 mo
(range, 3-191 mo) for subjects with EM leukemia and 60 mo
(range, 3-194 mo) for patients without EM leukemia.
Univariate analysis of outcomes showed no difference in
leukemia-free survival (LFS) or survival of subjects with or
without EM leukemia pretransplant. 5 y LFSs were 33% (95%
Figure 1. Probability of OS and DFS based on presence of EM disease
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were 36% (95% CI, 32-39%) vs 35 (95% CI, 34-37%; p¼0.96;
Figure 1). In a univariate analysis, 5 y survival did not differ
by site of EM leukemia (CNS, skin only, lymph node only,
other vs no EM leukemia; p¼0.28) or by time EM leukemia
occurred (at diagnosis, vs at transplant; p¼0.27). There was
no signiﬁcant difference in the rate of relapse in persons with
or without EM leukemia based on intensity of pretransplant
conditioning. After myelo-ablative conditioning the relative
risk of relapse was 1.09 (95% CI, 0.95-1.24; p¼0.21) and for
RIC was 0.89 (95% CI, 0.70e1.14; p¼0.36).
Conclusions: We found no impact of pretransplant
EM leukemia on LFS or survival after allotransplant for
AML. These data suggest decisions regarding transplants
should be independent of whether or not there is EM
leukemia.Figure 1. Overall Survival and Relapse Free Survival71
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Background: Acute myeloid leukemia (AML) associated with
inv(16), t(16;16), or t(8;21), known as core binding factor
(CBF) leukemias, are generally considered favorable risk.
However, relapse occurs in 30-40% of patients who achieve
ﬁrst complete remission (CR1). It is commonly assumed thatallogeneic hematopoietic stem cell transplantation (HCT) is
the preferred salvage strategy for relapsed disease, but there
are few data to support this clinical practice. To help guide the
practicing clinician, we retrospectively evaluated 67 consec-
utive patients with CBF-AML treated at a single institution
from 2000-2013 to evaluate the efﬁcacy of salvage HCT.
Patients and Methods: Of the 67 patients treated, 63
achieved a CR, 3 received supportive care and 1 died of
persistent disease. Five patients received a transplant in CR1
for high-risk features, including c-kit mutation (n¼3), ther-
apy-related AML (n¼1) and del-7q (n¼1). Thirty-two pa-
tients relapsed, with a median time to relapse of 11.6 months
(range 4.6-74.1 months), and 22 received salvage HCT in CR2
(n¼21) or refractory disease (n¼1). Reasons for not pro-
ceeding to salvage HCT included: infection (n¼3) or organ
toxicity (n¼1) precluding additional therapy, patient refusal
(n¼1) and lost to follow up (n¼4). One patient is undergoing
treatment with the goal to proceed to HCT. This report in-
cludes the 27 patients (median age 39 years, range 3-67.5)
who underwent HCT; patients received T-cell depleted (TCD)
graft (n¼17), double unit cord blood (DUCB, n¼5), DUCBwith
TCD-haploidentical donor graft (n¼2) or conventional graft
